Portola Pharmaceuticals Inc. is hoping to persuade FDA to approve its anticoagulant betrixaban based on the totality of data in its pivotal APEX study of high-risk, acute medically ill patients, even though the drug missed a key endpoint in the trial.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?